Topic:

April 2021

In July 2021, GSK received authorization under Health Canada’s Interim Order for Sotrovimab

In July 2021, GSK received authorization under Health Canada’s Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and adolescents. To read more please visit https://ca.gsk.com/en-ca/media/press-releases/gsk-receives-authorization-under-health-canada-s-interim-order-for-sotrovimab-for-injection-to-treat-covid-19-in-high-risk-adults-and-adolescents/

GSK also announced on January 6th that the Government of Canada has purchased additional doses: https://ca.gsk.com/en-ca/media/press-releases/gsk-announces-additional-purchase-agreements-with-the-government-of-canada-for-covid-19-monoclonal-antibody-therapy-sotrovimab/

Lupus Blog Articles:

Anifrolumab (Saphnelo) listed in SK

Read

Belimumab (Benlysta) listed in AB, NL & NIHB

Read

Belimumab (Benlysta) listed in ON

Read